DDI Study of Orelabrutinib

Healthy Person Clinical Trial

Official title:
A Phase I, Single-center, Open-label, Fixed-sequence Clinical Study to Evaluate the Effects of Multiple Administrations of Rifampin or Itraconazole on the Pharmacokinetic Characteristics of a Single Administration of Orelabrutinib Tablets in Healthy Subjects

Status Completed

Clinical Trial Summary

This is a phase I, single-center, open-label, fixed-sequence clinical study. The primary objective was to evaluate the effects of multiple administrations of rifampin or itraconazole on the pharmacokinetic characteristics of a single administration of orelabrutinib tablets in healthy Chinese subjects. The secondary objective was to evaluate the safety and tolerability of rifampicin or itraconazole combined with orelabrutinib tablets in healthy Chinese subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Healthy Person

Clinical Trial Details

NCT number	NCT05316857
Study type	Interventional
Source	Beijing InnoCare Pharma Tech Co., Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	December 16, 2021
Completion date	June 13, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06432738` - ZL-82 Double-blind Clinical Trial	Phase 1
Recruiting	`NCT05693233` - Effect of Soft Robotic Exosuit Assistance in Healthy People	N/A
Completed	`NCT01745835` - Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation	Phase 3
Terminated	`NCT03775473` - PROgastrine COlon DEpistage	N/A
Recruiting	`NCT06387966` - A Randomized, Double-blind,Dose-escalating, Single-dose, Oral Phase I Clinical Study of Flunotinib Healthy People	Phase 1
Completed	`NCT06213792` - Visuo-Vestibular Adaptation in Virtual Reality